Trial Profile
ANX-042 Healthy Volunteer Dose Escalation Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ANX 042 (Primary)
- Indications Acute heart failure; Chronic heart failure; Decompensated heart failure
- Focus Adverse reactions; First in man
- Sponsors Anexon
- 18 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Nov 2012 Planned number of patients changed from 18 to 30 as reported by ClinicalTrials.gov.